Flavia Longo

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rafael Rosell, Enric Carcereny, Radj Gervais et al. · The Lancet Oncology · 2012 · 5.5K citations · Full text

Oncology, Standard Chemotherapy, Randomised Phase 3 +8

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial

Marina Chiara Garassino, Olga Martelli, Massimo Broggini et al. · The Lancet Oncology · 2013 · 476 citations

Second-line Treatment, Oncology, Wild-type Egfr Tumours +9

Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab

Chiara Nicolazzo, Cristina Raimondi, M. Mancini et al. · Scientific Reports · 2016 · 267 citations · Full text

Long-term outcome after multimodality treatment for stage III thymic tumors

Federico Venuta, Erino Angelo Rendina, Flavia Longo et al. · The Annals of Thoracic Surgery · 2003 · 202 citations

Natural History of Non-Small-Cell Lung Cancer with Bone Metastases

Daniele Santini, Sandro Barni, Salvatore Intagliata et al. · Scientific Reports · 2015 · 136 citations · Full text